mTOR inhibitors in urinary bladder cancer. (Q38737064)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27235118 AND SRC:MED&resulttype=core&format=json

3 April 2020

review article

1 reference

title

mTOR inhibitors in urinary bladder cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27235118 AND SRC:MED&resulttype=core&format=json

3 April 2020

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27235118 AND SRC:MED&resulttype=core&format=json

3 April 2020

author name string

R Pinto-Leite

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27235118 AND SRC:MED&resulttype=core&format=json

3 April 2020

R Arantes-Rodrigues

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27235118 AND SRC:MED&resulttype=core&format=json

3 April 2020

Nuno Sousa

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27235118 AND SRC:MED&resulttype=core&format=json

3 April 2020

L Santos

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27235118 AND SRC:MED&resulttype=core&format=json

3 April 2020

publication date

27 May 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27235118 AND SRC:MED&resulttype=core&format=json

3 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27235118 AND SRC:MED&resulttype=core&format=json

3 April 2020

volume

37

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27235118 AND SRC:MED&resulttype=core&format=json

3 April 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27235118 AND SRC:MED&resulttype=core&format=json

3 April 2020

page(s)

11541-11551

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27235118 AND SRC:MED&resulttype=core&format=json

EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.

3 April 2020

cites work

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

21 January 2018

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

The present and future burden of urinary bladder cancer in the world

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Surgical advances in bladder cancer: at what cost?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Bladder cancer biomarker discovery using global metabolomic profiling of urine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Selective organ preservation with neo-adjuvant chemotherapy for the treatment of muscle invasive transitional cell carcinoma of the bladder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Molecular markers in bladder cancer: Novel research frontiers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Targeted therapy in advanced bladder cancer: what have we learned?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

The role of mechanistic target of rapamycin (mTOR) complexes signaling in the immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Current models of mammalian target of rapamycin complex 1 (mTORC1) activation by growth factors and amino acids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Mechanisms of mTOR inhibitor resistance in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Mammalian target of rapamycin complex I (mTORC1) activity in ras homologue enriched in brain (Rheb)-deficient mouse embryonic fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

mTOR Signaling in Protein Translation Regulation: Implications in Cancer Genesis and Therapeutic Interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

The mTOR (mammalian target of rapamycin) kinase maintains integrity of mTOR complex 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

The complexes of mammalian target of rapamycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Role of mTOR signaling in tumor cell motility, invasion and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Protor-1 is required for efficient mTORC2-mediated activation of SGK1 in the kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

PI3K/AKT pathway activation in bladder carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Genetic variations in PI3K-AKT-mTOR pathway and bladder cancer risk.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Rheb and mammalian target of rapamycin in mitochondrial homoeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

mTORC1 signaling: what we still don't know

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Structural analysis and functional implications of the negative mTORC1 regulator REDD1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Signal integration by mTORC1 coordinates nutrient input with biosynthetic output.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Control of Paip1-eukayrotic translation initiation factor 3 interaction by amino acids through S6 kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

The role of LKB1 and AMPK in cellular responses to stress and damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Amino acids activate mammalian target of rapamycin complex 2 (mTORC2) via PI3K/Akt signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

TOR complex 2: a signaling pathway of its own.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

PI3K and mTOR signaling pathways in cancer: new data on targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Molecular mechanism of the dual activity of 4EGI-1: Dissociating eIF4G from eIF4E but stabilizing the binding of unphosphorylated 4E-BP1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

mTOR-targeted therapy of cancer with rapamycin derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

S6K1 and 4E-BP1 are independent regulated and control cellular growth in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

The mammalian target of rapamycin signaling network and gene regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

TOR signaling in growth and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

The Role of mTOR Inhibitors for the Treatment of B-Cell Lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

mTOR signaling in growth control and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

The mTOR pathway controls cell proliferation by regulating the FoxO3a transcription factor via SGK1 kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

The intersection between aging and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Expanding therapeutic targets in bladder cancer: the PI3K/Akt/mTOR pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Molecular alterations of PI3K/Akt/mTOR pathway: a therapeutic target in endometrial cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Characteristic mTOR activity in Hodgkin-lymphomas offers a potential therapeutic target in high risk disease--a combined tissue microarray, in vitro and in vivo study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Expression microarray meta-analysis identifies genes associated with Ras/MAPK and related pathways in progression of muscle-invasive bladder transition cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

The mTOR signalling pathway in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

The Role of PI3K/Akt/mTOR Signaling in Gastric Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

The Akt-associated microRNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Invasive Bladder Cancer: Genomic Insights and Therapeutic Promise

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Emerging therapeutic targets in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Comprehensive molecular characterization of urothelial bladder carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Targeting the genetic alterations of the PI3K-AKT-mTOR pathway: its potential use in the treatment of bladder cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Mammalian target of rapamycin (mTOR) regulates cellular proliferation and tumor growth in urothelial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Activation of the PI3K/Akt/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Chromosomal deletions in bladder cancer: shutting down pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Inactivation of p53 and Pten promotes invasive bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Role of the mTOR Pathway in the Progression and Recurrence of Bladder Cancer: An Immunohistochemical Tissue Microarray Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Antiproliferative and overadditive effects of rapamycin and FTY720 in pancreatic cancer cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Effect of sirolimus on urinary bladder cancer T24 cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Antitumor effects of rapamycin in pancreatic cancer cells by inducing apoptosis and autophagy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Exploring new frontiers: sirolimus as a pharmacokinetic modulator in advanced cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Temsirolimus: a safety and efficacy review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Rapamycin passes the torch: a new generation of mTOR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Updates of mTOR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Differentiating mTOR inhibitors in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Everolimus for advanced pancreatic neuroendocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Effects of mTOR Inhibitor Everolimus (RAD001) on Bladder Cancer Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Phase II trial of temsirolimus alone and in combination with irinotecan for KRAS mutant metastatic colorectal cancer: outcome and results of KRAS mutational analysis in plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

A mechanism for synergy with combined mTOR and PI3 kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

In vivo and in vitro effects of RAD001 on bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Intravesical delivery of rapamycin suppresses tumorigenesis in a mouse model of progressive bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Effect of mTOR inhibitors in nude mice with endometrial carcinoma and variable PTEN expression status

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Synergistic interactions between sorafenib and everolimus in pancreatic cancer xenografts in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Antitumor effect of everolimus in preclinical models of high-grade gastroenteropancreatic neuroendocrine carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Therapeutic efficiency of everolimus and lapatinib in xenograft model of human colorectal carcinoma with KRAS mutation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

mTORC1 inhibitors suppress meningioma growth in mouse models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Coordinate autophagy and mTOR pathway inhibition enhances cell death in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Inhibition of mTOR by temsirolimus contributes to prolonged survival of mice with pleural dissemination of non‐small‐cell lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Everolimus in advanced pancreatic neuroendocrine tumors: the clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Phase II study of everolimus in metastatic urothelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Not all substrates are treated equally: implications for mTOR, rapamycin-resistance and cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Circulating miRNAs in cancer: from detection to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Reprogramming of the microRNA transcriptome mediates resistance to rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Chemical Inhibitors and microRNAs (miRNA) Targeting the Mammalian Target of Rapamycin (mTOR) Pathway: Potential for Novel Anticancer Therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Targeting the mTOR signaling network for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Biomarkers in bladder cancer: translational and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Genomic characterization of three urinary bladder cancer cell lines: understanding genomic types of urinary bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Current and recent clinical trials for perioperative systemic therapy for muscle invasive bladder cancer: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Molecular mechanisms of cisplatin resistance in bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Temsirolimus improves cytotoxic efficacy of cisplatin and gemcitabine against urinary bladder cancer cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

The combination of an mTORc1/TORc2 inhibitor with lapatinib is synergistic in bladder cancer in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Effects of combining rapamycin and resveratrol on apoptosis and growth of TSC2-deficient xenograft tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Everolimus Augments the Effects of Sorafenib in a Syngeneic Orthotopic Model of Hepatocellular Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Partial response of a rare malignant metastatic diffuse tenosynovial giant cell tumor with benign histologic features, treated with SCH 717-454, an insulin growth factor receptor inhibitor, in combination with everolimus, an MTOR inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Feasibility of sequential use of sunitinib and temsirolimus in advanced renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Mutations in critical domains confer the human mTOR gene strong tumorigenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5083-1

Patient-derived xenografts reveal limits to PI3K/mTOR- and MEK-mediated inhibition of bladder cancer

21 January 2018

1 reference

12 December 2020

Current development of the second generation of mTOR inhibitors as anticancer agents

1 reference

12 December 2020

The Mammalian target of rapamycin inhibitors in breast cancer: current evidence and future directions

1 reference

12 December 2020

Sirolimus: a new immunosuppressant.

1 reference

12 December 2020

Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers

1 reference

12 December 2020

1 reference

12 December 2020

Hot topics in urological health economics. A mini review.

1 reference

12 December 2020

Phospho-mTOR in non-tumour and tumour bladder urothelium: Pattern of expression and impact on urothelial bladder cancer patients

1 reference

12 December 2020

mTOR pathway in colorectal cancer: an update

1 reference

12 December 2020

A new initiative on precision medicine

1 reference

12 December 2020

The effects of sirolimus on urothelial lesions chemically induced in ICR mice by BBN.

1 reference

12 December 2020

mTOR-dependent cell survival mechanisms

1 reference

12 December 2020

The synergistic effect of rapamycin combined with 5-fluorouracil in BALB/cByJNarl mice bearing CT-26 tumor cells

1 reference

12 December 2020

mTOR inhibitor RAD001 (everolimus) induces apoptotic, not autophagic cell death, in human nasopharyngeal carcinoma cells

1 reference

12 December 2020

Therapeutic rationale for mTOR inhibition in advanced renal cell carcinoma.

1 reference

12 December 2020

10.1007/S13277-016-5083-1

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27235118 AND SRC:MED&resulttype=core&format=json

Dimensions Publication ID

3 April 2020

1034830116

0 references

Fatcat ID

release_l7f5fo3p5redthlyzdkoq4svqe

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/l7f5fo3p5redthlyzdkoq4svqe

24 November 2022

mapped directly with Wikidata item

1 reference